Inotek Pharma (ITEK) Posts Narrwer-than-Expected Q1 Loss of 21c/Share

Inotek Pharma (NASDAQ: ITEK) reported Q1 EPS of ($0.21), $0.19 better than the analyst estimate of ($0.40).

Cash and cash equivalents as of March 31, 2015 were $53.1 million, compared to $3.6 million as of December 31, 2014.

For earnings history and earnings-related data on Inotek Pharma (ITEK) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Audioeye, Inc. (AEYE) Misses Q2 EPS by 28c; Offer Guidance
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02